IBT On Other Exchanges
Symbol
Exchange
Stuttgart
Venture
OTC US

ibex technologies inc (IBT) Snapshot

Open
--
Previous Close
--
Day High
--
Day Low
--
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
--
Average Volume 10 Days
--
EPS TTM
--
Shares Outstanding
--
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for IBEX TECHNOLOGIES INC (IBT)
\

Related News

No related news articles were found.

ibex technologies inc (IBT) Related Businessweek News

No Related Businessweek News Found

ibex technologies inc (IBT) Details

IBEX Technologies Inc., through its subsidiaries, manufactures and markets enzymes for biomedical use in Canada, the United States, the United Kingdom, and internationally. It offers a portfolio of recombinant glycosaminoglycan lyases, including Heparinase I, Heparinase II, Heparinase III, Chondroitinase AC, and Chondroitinase B. The company also manufactures and markets a range of arthritis assays, which are used in osteoarthritis research. In addition, it provides services, such as filling and lyophilization of diagnostic disposables for medical devices; and custom fermentation and purification of enzymes, as well as contract manufacturing. Further, the company makes and sells proteins extracted from botanicals. It serves manufacturers of medical devices, quality control labs, and academic research institutions. The company was founded in 1986 and is based in Montreal, Canada.

Founded in 1986

ibex technologies inc (IBT) Top Compensated Officers

President, CEO & Chairman
Total Annual Compensation: C$216.9K
Director of Finance & Secretary
Total Annual Compensation: C$147.4K
Vice President of Administration
Total Annual Compensation: C$163.1K
Compensation as of Fiscal Year 2018.
ibex technologies inc
Ibex Technologies, Inc. Reports Earnings Results for the Second Quarter Ended January 31, 2019

IBEX Technologies Inc. announced earnings results for the second quarter ended January 31, 2019. For the second quarter, the company announced sales was CAD 1.432 million compared to CAD 892,774 a year ago. Operating income was CAD 55,756 compared to operating loss of CAD 321,047 a year ago. Net income was CAD 42,798 compared to net loss of CAD 415,596 a year ago. For the half year, sales was CAD 2.472 million compared to CAD 2.075 million a year ago. Operating loss was CAD 180,946 compared to CAD 278,238 a year ago. Net loss was CAD 165,943 compared to CAD 285,737 a year ago.

IBEX Technologies Inc. Reports Plans to Close Iowa Production Facility

IBEX Technologies Inc. reported that it plans to close its Iowa production facility as of July 31, 2019. The Iowa production facility came with the 2013 acquisition of Bio-Research Products Inc. BRP produces, among other things, a series of enzymes used in clinical diagnostics which complements the IBEX enzyme product line. The production of the BRP clinical diagnostics enzymes will be transferred to the IBEX Montréal production facility. The North Liberty facility will be put up for sale as a functioning enzyme production facility with all the equipment required for the production of clinical diagnostic enzymes and botanical extracts. The property consists of a fermentation suite with a 300 litre bio-reactor, 2,200 square feet of wet-lab space, 1,200 square feet of production space for downstream production and 4,450 square feet of warehouse space. The facility sits on 5.43 acres of land, of which 3.54 acres is available for future expansion. The Company will book approximately $150,000 in shut-down related costs in the fourth quarter.

IBEX Technologies Inc. Reports Earnings Results for the First Quarter Ended October 31, 2018

IBEX Technologies Inc. reported earnings results for the first quarter ended October 31, 2018. For the quarter, the company's reported revenue was $1,039,473 compared to $1,183,013 for the same period a year ago. Net loss was $208,741 compared to profit of $129,859 for the same period a year ago. Loss per share was $0.01 compared to earnings per share of $0.01 for the same period a year ago.

 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

IBT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for IBT.
View Industry Companies
 

Industry Analysis

IBT

Industry Average

Valuation IBT Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 0.8x
Price/Book 0.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales NM Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact IBEX TECHNOLOGIES INC, please visit www.ibex.ca. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.